These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide. Madarová J, Lukesová M, Hlobilková A, Riháková P, Murray PG, Student V, Vojtsek B, Kolár Z. Neoplasma; 2001 Jun 01; 48(5):419-24. PubMed ID: 11845989 [Abstract] [Full Text] [Related]
11. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. Terada N, Shimizu Y, Yoshida T, Maeno A, Kamba T, Inoue T, Nakamura E, Kamoto T, Ogawa O. Prostate; 2010 Feb 15; 70(3):252-61. PubMed ID: 19790238 [Abstract] [Full Text] [Related]
12. Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells. Morrissey C, Brown M, O'Sullivan J, Weathered N, Watson RW, Tenniswood M. Int J Urol; 2007 Jun 15; 14(6):545-51. PubMed ID: 17593102 [Abstract] [Full Text] [Related]
13. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Cancer Res; 2003 Jan 01; 63(1):149-53. PubMed ID: 12517791 [Abstract] [Full Text] [Related]
14. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O. Cancer Res; 2005 Nov 01; 65(21):9611-6. PubMed ID: 16266977 [Abstract] [Full Text] [Related]
15. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291. Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H. Prostate; 2011 Sep 01; 71(12):1344-56. PubMed ID: 21308717 [Abstract] [Full Text] [Related]
16. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels. Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC. Prostate; 2010 Feb 01; 70(2):179-89. PubMed ID: 19790234 [Abstract] [Full Text] [Related]
17. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Can J Urol; 2009 Oct 01; 16(5):4806-12. PubMed ID: 19796455 [Abstract] [Full Text] [Related]
20. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y. Prostate; 2010 Apr 01; 70(5):457-66. PubMed ID: 19902465 [Abstract] [Full Text] [Related] Page: [Next] [New Search]